

Tucatinib HER2CLIMB

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Tucatinib HER2CLIMB

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: HER2-positive locally advanced or metastatic breast cancer after at least 2 prior anti-HER2 treatment regimes
 Experimental Arm: Tucatinib + Trastuzumab + capecitabine
 Control Arm: Placebo, trastuzumab + capecitabine

